PharmacoEconomics

Acknowledgements

Cost of Illness: An Ongoing Battle Worth Fighting

Paul E. Greenberg

“Can We Declare Victory and Move On?” The Case Against Funding Burden-of-Disease Studies

Steven Kymes

A Guide to Handling Missing Data in Cost-Effectiveness Analysis Conducted Within Randomised Controlled Trials

Rita Faria, Manuel Gomes, David Epstein, Ian R. White

Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal

Nicholas R. Latimer, Christopher Carroll, Ruth Wong, Paul Tappenden, Michael C. Venning, Raashid Luqmani

A Review of the Methodological Challenges in Assessing the Cost Effectiveness of Pharmacist Interventions

Rachel A. Elliott, Koen Putman, James Davies, Lieven Annemans

A Review of the Economic Burden of Glioblastoma and the Cost Effectiveness of Pharmacologic Treatments

Andrew Messali, Reginald Villacorta, Joel W. Hay

The Humanistic Burden of Head and Neck Cancer: A Systematic Literature Review

Erika Wissinger, Ingolf Griebsch, Juliane Lungershausen, Michael Byrnes, Karin Travers, Chris L. Pashos

Comparative Economics of a 12-Gene Assay for Predicting Risk of Recurrence in Stage II Colon Cancer

Steven R. Alberts, Tiffany M. Yu, Robert J. Behrens, Lindsay A. Renfro, Geetika Srivastava, Gamini S. Soori, Shaker R. Dakhil, Rex B. Mowat, John P. Kuebler, George P. Kim, Miroslaw A. Mazurczak, John Hornberger

Comment on: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

Afschin Gandjour

Authors’ Reply to Gandjour: “Are Current Cost-Effectiveness Thresholds for Low- and Middle-Income Countries Useful? Examples from the World of Vaccines”

A. T. Newall, M. Jit, R. Hutubessy

Objectivity and Equity: Clarity Required. A Response to Hill and Olson

Mike Paulden, James F. O’Mahony, Anthony J. Culyer, Christopher McCabe